Macro‐and microvascular endothelial dysfunction in diabetes: 糖尿病诱导的内皮细胞功能损伤

Y Shi, PM Vanhoutte - Journal of diabetes, 2017 - Wiley Online Library
血管内皮细胞和内皮细胞释放的活性因子是调控血管舒张功能的重要因素. 糖尿病是慢性心血管
疾病的高危因素之一. 目前认为高糖和糖尿病引起的内皮细胞功能障碍是造成血管功能改变 …

[HTML][HTML] Mechanisms of macular edema: beyond the surface

A Daruich, A Matet, A Moulin, L Kowalczuk… - Progress in retinal and …, 2018 - Elsevier
Macular edema consists of intra-or subretinal fluid accumulation in the macular region. It
occurs during the course of numerous retinal disorders and can cause severe impairment of …

Therapeutic targeting of the angiopoietin–TIE pathway

P Saharinen, L Eklund, K Alitalo - Nature Reviews Drug Discovery, 2017 - nature.com
The endothelial angiopoietin (ANG)–TIE growth factor receptor pathway regulates vascular
permeability and pathological vascular remodelling during inflammation, tumour …

Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication

JB Funcke, PE Scherer - Journal of lipid research, 2019 - ASBMB
The breakthrough discoveries of leptin and adiponectin more than two decades ago led to a
widespread recognition of adipose tissue as an endocrine organ. Many more adipose tissue …

Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data

AM Joussen, F Ricci, LP Paris, C Korn… - Eye, 2021 - nature.com
The ang opoietin/t yrosine kinase with i mmunoglobulin and e pidermal growth factor
homology domains (Ang/Tie) pathway is an emerging key regulator in vascular development …

Targeting pericytes for therapeutic approaches to neurological disorders

J Cheng, N Korte, R Nortley, H Sethi, Y Tang… - Acta …, 2018 - Springer
Many central nervous system diseases currently lack effective treatment and are often
associated with defects in microvascular function, including a failure to match the energy …

[HTML][HTML] Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 …

J Sahni, SS Patel, PU Dugel, AM Khanani, CD Jhaveri… - Ophthalmology, 2019 - Elsevier
Purpose The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel
bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF …

Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab

M Khan, AA Aziz, NA Shafi, T Abbas, AM Khanani - Cells, 2020 - mdpi.com
This review summarizes the latest findings in the literature of Angiopoietin-2 (Ang-2),
Tyrosine-protein kinase receptor (Tie-2) complex, and faricimab along with their involvement …

Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases

JT Regula, P Lundh von Leithner, R Foxton… - EMBO molecular …, 2016 - embopress.org
Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial
growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases …

Tie1 controls angiopoietin function in vascular remodeling and inflammation

EA Korhonen, A Lampinen, H Giri… - The Journal of …, 2016 - Am Soc Clin Investig
The angiopoietin/Tie (ANG/Tie) receptor system controls developmental and tumor
angiogenesis, inflammatory vascular remodeling, and vessel leakage. ANG1 is a Tie2 …